Subcutaneous immunoglobulin infusion: A new therapeutic option in chronic inflammatory demyelinating polyneuropathy

Lee, Dong Hoon; Linker, Ralf A.; Paulus, Walter; Schneider‐Gold, Christiane; Chan, Andrew; Gold, Ralf

doi:10.1002/mus.20909

Cited by 94 publications

(61 citation statements)

References 29 publications

(21 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Toxicity and tolerability have been tested and the use has been approved by the FDA. s.c. IgG has been shown to be safe in individuals with immunological neurological diseases like multifocal motor neuropathy and chronic inflammatory demyelinating polyneuropathy [8,9,10]. Although the number of the cases is small, this therapy is well tolerated and the reports suggest a good response to s.c. IgG treatment.…”

Section: Discussionmentioning

confidence: 99%

Susac Syndrome Treated with Subcutaneous Immunoglobulin

Kleffner

Dörr²,

Duning³

et al. 2013

Eur Neurol

View full text Add to dashboard Cite

Background: Susac syndrome is a rare disease characterized by the triad of encephalopathy, branch retinal artery occlusion, and sensorineural hearing loss mainly affecting young women. The finding of antibodies against the endothelium in the sera of these patients has supported the hypothesis of an autoimmune endotheliopathy of the brain, inner ear and retina. Because of the rarity of the disease, treatment is based on the knowledge of case reports and small case series. Medical therapy consists of glucocorticoids, immunosuppressants, acetyl salicylic acid, and immunomodulatory agents such as intravenous immunoglobulin. Methods: We present the case histories of 2 young women with Susac syndrome presenting with several episodes of encephalopathy, branch retinal artery occlusions, and hearing loss that were treated with different immunosuppressive drugs, glucocorticoids and intravenous immunoglobulin. In the course of the disease, the treatment was successfully switched to subcutaneous immunoglobulin without any further relapse in both patients. Conclusion: We conclude that the application of subcutaneous immunoglobulin is easy to learn, helps to reduce in-hospital costs and enables a more flexible everyday life. The treatment with subcutaneous immunoglobulin helps to reduce immunosuppressants and appears to prevent relapses.

show abstract

Section: Discussionmentioning

confidence: 99%

Susac Syndrome Treated with Subcutaneous Immunoglobulin

Kleffner

Dörr²,

Duning³

et al. 2013

Eur Neurol

View full text Add to dashboard Cite

show abstract

“…[14][15][16][17] In Germany, SCIG was found to be 50% less expensive than IVIG due to the reduced costs for treatment procedures and the avoided absence from work. 15 SCIG was predicted to be more cost-effective than hospital-based IVIG in Canada.…”

Section: Introductionmentioning

confidence: 99%

Cost-minimization Analysis of IgPro20, a Subcutaneous Immunoglobulin, in Japanese Patients With Primary Immunodeficiency

Igarashi

Kanegane

Kobayashi

et al. 2014

Clinical Therapeutics

View full text Add to dashboard Cite

show abstract

“…Long-term interval treatment has also been shown to have some beneficial effects [28,56,58,82,102,116]. Preliminary investigations have shown a comparable efficacy of subcutaneous (scIg) and intravenous immunoglobulin (ivIg) administration [75].…”

Section: Chronic Inflammatory Demyelinating Polyneuropathy (Cidp)mentioning

confidence: 98%